Imlygic.com

Keyword Suggestion

Imlygic

Imlygic package insert

Imlygic pi

Imlygic fda

Imlygic sales

Imlygic ema

Imlygic price

Imlygic talimogene laherparepvec

Imlygic idt biologika

Imlygic clinical trial

Imlygic fda approval

Imlygic gene therapy

Domain Informations

Whois Informations
Top 10 Domain Provider

Imlygic.com lookup results from whois.markmonitor.com server:

Network

Owner

Abuse

Technical support

Domain Provider	Number Of Domains
godaddy.com	286730
namecheap.com	101387
networksolutions.com	69118
tucows.com	52617
publicdomainregistry.com	39120
whois.godaddy.com	32793
enomdomains.com	23825
namesilo.com	21429
domains.google.com	21384
cloudflare.com	20573
gmo.jp	18110
name.com	17601
fastdomain.com	14708
register.com	13495
net.cn	12481
ionos.com	12416
ovh.com	12416
gandi.net	12305
registrar.amazon.com	12111

Host Informations

Check all domain's dns records

See Web Sites Hosted on 34.213.2.255

Fetching Web Sites Hosted

Site Inspections

Port Scanner (IP: 34.213.2.255)

› Ftp: 21

› Ssh: 22

› Telnet: 23

› Smtp: 25

› Dns: 53

› Http: 80

› Pop3: 110

› Portmapper, rpcbind: 111

› Microsoft RPC services: 135

› Netbios: 139

› Imap: 143

› Ldap: 389

› Https: 443

› SMB directly over IP: 445

› Msa-outlook: 587

› IIS, NFS, or listener RFS remote_file_sharing: 1025

› Lotus notes: 1352

› Sql server: 1433

› Point-to-point tunnelling protocol: 1723

› My sql: 3306

› Remote desktop: 3389

› Session Initiation Protocol (SIP): 5060

› Virtual Network Computer display: 5900

› X Window server: 6001

› Webcache: 8080

Spam Check (IP: 34.213.2.255)

› Dnsbl-1.uceprotect.net:

› Dnsbl-2.uceprotect.net:

› Dnsbl-3.uceprotect.net:

› Dnsbl.dronebl.org:

› Dnsbl.sorbs.net:

› Spam.dnsbl.sorbs.net:

› Bl.spamcop.net:

› Recent.dnsbl.sorbs.net:

› All.spamrats.com:

› B.barracudacentral.org:

› Bl.blocklist.de:

› Bl.emailbasura.org:

› Bl.mailspike.org:

› Bl.spamcop.net:

› Cblplus.anti-spam.org.cn:

› Dnsbl.anticaptcha.net:

› Ip.v4bl.org:

› Fnrbl.fast.net:

› Dnsrbl.swinog.ch:

› Mail-abuse.blacklist.jippg.org:

› Singlebl.spamgrouper.com:

› Spam.abuse.ch:

› Spamsources.fabel.dk:

› Virbl.dnsbl.bit.nl:

› Cbl.abuseat.org:

› Dnsbl.justspam.org:

› Zen.spamhaus.org:

Email address with imlygic.com

Found 0 emails of this domain

Recent Searched Sites

› Faclettre.univ-tlemcen.dz (6 seconds ago) / DZ

› Arizonaboattop.com (2 seconds ago) / US

› Tcsagency.com (2 seconds ago) / US

› Leappayments.com (18 seconds ago) / US

› Facehack.org (0 seconds ago) / AU

› Economitza.com (10 seconds ago) / ES

› Tburgpto.com (9 seconds ago) / US

› Nnsuperseafood.com (0 seconds ago) / US

› Www9.javfun.me (5 seconds ago) / US

› Economy-inn-north-randall.hotelmix.co.uk (0 seconds ago) / US

› Pcbtronic.pl (7 seconds ago) / PL

› Tempra.com.ar (2 seconds ago) / AR

› Miomarket.ru (2 seconds ago) / RU

› Mcct.by (0 seconds ago) / BY

› Kiskeya.life (10 seconds ago) / US

› Selectiontoperfection.com (1 seconds ago) / FI

› Cartera.com (3 seconds ago) / US

› Imlygic.com (0 seconds ago) / US

› Ninestarelectric.smarthub.coop (10 seconds ago) / US

› Economo.ro (4 seconds ago) / DE

List of our tools

Emails by domain

Mobile Friendly Check

Page Speed Check

DNS Lookup

Ports Scan

Sites on host

Sitemap Generator

Websites Listing

We found Websites Listing below when search with imlygic.com on Search Engine

IMLYGIC® (talimogene laherparepvec) Oncolytic Viral …

IMLYGIC ® is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use: IMLYGIC ® …

Imlygichcp.com

IMLYGIC | FDA

IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in …

Fda.gov

IMLYGIC ® Has Special OPERATIONS AND HANDLING …

For more information, call 1-866-IMLYGIC (465-9442) 1-866-IMLYGIC (465-9442); choose Option 1 for Health Care Providers, then Option 2 for ordering. Close ☒. Key Points to Consider: IMLYGIC ® should be protected from light …

Imlygichcp.com

Imlygic - FDA prescribing information, side effects and uses

2022-01-01 · Imlygic (talimogene laherparepvec) is a sterile suspension for intralesional injection. Imlygic is a live, attenuated HSV-1 that has been genetically modified to express huGM-CSF. The parental virus for Imlygic …

Drugs.com

IMLYGIC

IMLYGIC® Prescriber’s (Doctor’s) Name: Doctor’s Phone Number: Name of Centre/Institution (if applicable): Start Date of IMLYGIC® Treatment: IMLYGIC® Batch Numbers (Dates Administered): Product manufacturer and license holder: Amgen Europe B.V. This card format and content has been checked and approved by the Ministry of Health in June 2017

Mohpublic.z6.web.core.windows.net

Page 1 of 16 - Amgen

IMLYGIC and should not come into direct contact with the IMLYGIC injection sites, dressings, or body fluids of treated patients [see Warnings and Precautions (5.1)]. Avoid accidental exposure to IMLYGIC and follow below instructions for preparation, administration, and handling of IMLYGIC: Wear personal protective equipment (protective gown or laboratory coat, safety glasses or …

Pi.amgen.com

Imlygic - Gene Therapy Net

Imlygic is an oncolytic viral therapy with attenuated life herpes simplex virus type 1 (HSV-1). In HSV-1, two genes are removed and one gene is added. The genes who are removed originally code for the proteins infected cell protein 34.5 (ICP34.5) and infected cell protein 47 (ICP47). ICP34.5 blocks the response of healthy cells to stop ...

Genetherapynet.com

IMLYGIC

2020-12-22 · INDICATION IMLYGIC® is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use: IMLYGIC® has not been shown to improve overall survival or have an effect on visceral metastases.

Cdn.imlygichcp.com

FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First …

About IMLYGIC (talimogene laherparepvec) IMLYGIC is a genetically modified herpes simplex virus type 1 injected directly into tumors where it replicates inside tumors and produces GM-CSF, an immunostimulatory protein. IMLYGIC then causes the tumor to rupture and die in a process called lysis. The rupture of the tumor causes the release of tumor ...

Amgen.com

Imlygic Injection: Uses, Side Effects, Interactions, Pictures

Find patient medical information for Imlygic injection on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Webmd.com

IMLYGIC 1x10e8 UFP/ml Sol. iny. - Equivalencias Internacionales 磊

Equivalencias Internacionales de IMLYGIC 1x10e8 UFP/ml Sol. iny.(Talimogen laherparepvec) de AMGEN, S.A., además de otros datos, como sus indicaciones.

Vademecum.es

Imlygic (Talimogene Laherparepvec Suspension for Intralesional ...

2021-11-29 · INDICATIONS. IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.. Limitations Of Use. IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases.

Rxlist.com

Imlygic™ (talimogene laherparepvec)

Imlygic (talimogene laherparepvec) over either therapy given alone. Imlygic (talimogene laherparepvec) is not recommended per NCH Policy or NCH Pathway for combination therapy with Checkpoint Inhibitors, e.g., ipilimumab, nivolumab, and pembrolizumab, except in members who have failed all alternative systemic therapies. 3. The member has stage IIIB, IIIC, or …

Emblemhealth.com

IMLYGIC 1x10e8 UFP/ml Sol. iny. - Interacciones

Analizador de Interacciones de IMLYGIC 1x10e8 UFP/ml Sol. iny.(Talimogen laherparepvec) de AMGEN, S.A., además de otros datos, como sus indicaciones.

Vademecum.es

IMLYGIC- talimogene laherparepvec injection, suspension

IMLYGIC (talimogene laherparepvec) is a sterile suspension for intralesional injection. IMLYGIC is a live, attenuated HSV-1 that has been genetically modified to express huGM-CSF. The parental virus for IMLYGIC was a primary isolate, which was subsequently altered using recombinant methods to result in gene deletions and insertions.

Dailymed.nlm.nih.gov

Imlygic SDS Rev 10 FINAL 20180503 - Amgen

2018-05-02 · IMLYGIC® Revision Number: 10 Date Issued: May 02, 2018 Page 3 of 4 First Aid/ In the event of accidental exposure through a splash to the eyes or mucous membranes, Treatment: flush with clean water for at least 15 minutes. In the event of exposure to broken skin or needle stick, clean the site thoroughly with soap and water or a skin disinfectant.

Msds.amgen.com

IMLYGIC Limitations of use : IMLYGIC PRODUCT ORDERING …

2020-12-22 · INDICATION IMLYGIC® is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use : IMLYGIC® has not been shown to improve overall survival or have an effect on visceral metastases. IMPORTANT SAFETY …

Cdn.imlygichcp.com

再生元支持,溶瘤病毒公司Vyriad,融资3000万美元

2022-05-19 · 到目前为止， Imlygic 仍然是唯一获得 FDA 批准的溶瘤病毒疗法。 2022 年 5 月 17 日， Vyriad, Inc. 是一家临床阶段生物技术公司，开发用于治疗多种癌症的溶瘤病毒疗法，今天宣布获得 2950 万美元的新资金，由斯坦恩种子农场的 Harry Stine 先生领导，现有投资者也参与其中。

Aisoutu.com

Imlygic - Summary of Product Characteristics (SmPC) - (emc)

2022-04-07 · Imlygic is provided in single-use vials of 1 mL each in two different concentrations: • 10 6 (1 million) PFU/mL - For initial dose only. • 10 8 (100 million) PFU/mL - For all subsequent doses. The total injection volume for each treatment visit should be up to a maximum of 4 mL.

Medicines.org.uk

Imlygic (talimogene laherparepvec) dosing, indications, …

Contraindications. Immunocompromised patients; talimogene laherparepvec is a live, attenuated herpes simplex virus and may cause life-threatening disseminated herpetic infection in patients who are immunocompromised; do not administer to immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS …

Reference.medscape.com

Domains Expiration Date Updated

Site	Provider	Expiration Date
getsocialnetwork.com	namecheap.com	-1 Years, -152 Days
munshi10.com	onlinenic.com	-1 Years, -351 Days
sambapinto.com	publicdomainregistry.com	-1 Years, -344 Days
smartonlineexam.com	godaddy.com	-1 Years, -124 Days
pelletizerknivesinc.com	networksolutions.com	7 Years, 306 Days
ktmlabs.com	namecheap.com	-1 Years, -333 Days
saskkartclub.com	publicdomainregistry.com	2 Years, 192 Days
lmlmusicpresents.com	godaddy.com	-2 Years, -37 Days
fsn-ltd.com	enomdomains.com	-2 Years, -191 Days
getkempt.com	namecheap.com	-1 Years, -347 Days

Browser All